Progressive renal insufficiency related to ALK inhibitor, alectinib

Kojiro Nagai¹*, Hiroyuki Ono¹, Motokazu Matsuura¹, Michael Hann³, Sayo Ueda¹, Sakiya Yoshimoto¹, Masanori Tamaki¹, Taichi Murakami¹, Hideharu Abe¹, Hisashi Ishikura² and Toshio Doi¹

¹Department of Nephrology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan, ²Department of Surgery, Division of Thoracic Surgery, Tokushima Red Cross Hospital, Tokushima, Japan, and ³Department of the Directorate for Medical Services, US Navy Hospital, Yokosuka, Japan

*Correspondence address. Department of Nephrology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, 3-18-15, Kuramoto-cho, Tokushima 770-8503, Japan. Tel: +81-(0)88-633-7184; Fax: +81-(0)88-633-9245; E-mail: knagai@tokushima-u.ac.jp

Abstract

Alectinib is a second generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor and is generally effective and tolerated in patients who have demonstrated disease progression or adverse effects while on the first generation inhibitor, crizotinib. ALK inhibitors can cause a reversible chronic increase of serum creatinine concentration; however, they rarely induce progressive renal insufficiency. We herein report a case of a 68-year-old woman diagnosed with ALK-positive advanced non-small cell lung cancer and who received ALK inhibitors. Due to dysgeusia and transaminitis, her medication was switched from crizotinib to alectinib. Rapid progressive glomerulonephritis developed 1 year after the initiation of alectinib treatment. A renal biopsy revealed unique kidney lesions in both tubules and glomeruli. Glucocorticoid therapy partially reversed kidney impairment. However, re-administration of alectinib caused kidney dysfunction, which was improved by the cessation of alectinib. Our case suggests that much attention should be paid to kidney function when using ALK inhibitors.

INTRODUCTION

Alectinib is a tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), applicable in patients with advanced non-small cell lung cancer with ALK rearrangements [1]. Common adverse effects reported in alectinib trials include constipation, dysgeusia, vomiting, neutropenia and transaminitis [2]. ALK inhibitors can cause a chronic increase of serum creatinine concentration, which usually occurs within 2 weeks of drug initiation and then levels out [3, 4]. However, ALK inhibitors rarely induce progressive renal insufficiency. We herein describe a case of rapid progressive glomerulonephritis occurring in a patient who had taken alectinib for 1 year. A renal biopsy revealed unique kidney damage in both tubules and glomeruli related to alectinib.

CASE REPORT

A 68-year-old woman was diagnosed with ALK-positive advanced non-small cell lung cancer in the left lower lobe and left iliac bone metastasis (cT2N0M1b, Stage IV). Disease progression was observed after four cycles of pemetrexed and carboplatin combination chemotherapy. Five hundred milligram...
per day of crizotinib was administered for 2 months and worked well to reduce tumor size. The patient's serum creatinine concentration increased from 0.68 to 0.75 mg/dl (estimated glomerular filtration rate (eGFR) 65.7 to 59.0 ml/min/1.73 m²) over 2 months. However, due to dysgeusia and transaminitis, crizotinib was substituted for 600 mg/day of alectinib. Prior to alectinib treatment, the patient's creatinine was 0.72 mg/dl (eGFR 61.4 ml/min/1.73 m²). Alectinib was effective and well tolerated in the patient. After 1 year of treatment with alectinib, the patient reported bubbling urine and low extremity edema. Urinaryysis revealed proteinuria of 3.42 g/g creatinine and gross hematuria. Urine N-acetyl-beta-D-glucosaminidase (NAG) and β2-microglobulin (β2-MG) were also elevated to 61.9 U/l (reference range <11.2 U/l) and 15 841 μg/l (<360 μg/l), respectively. Serum creatinine concentration increased from 0.90 to 3.66 mg/dl (eGFR 47.9 to 10.3 ml/min/1.73 m²) during the prior 3 months. Serum creatinine concentration decreased to 2.63 mg/dl (eGFR 14.8 ml/min/1.73 m²). Proteinuria and hematuria disappeared and the values of urine NAG and β2-MG normalized. Thus, 600 mg/day of alectinib was restarted and the glucocorticoid dose was tapered. Serum creatinine concentration gradually increased and reached a peak level of 3.91 mg/dl (eGFR 9.6 ml/min/1.73 m²) without developing proteinuria, hematuria, urine NAG and β2-MG elevation for 6 months after alectinib re-administration. Due to patient preference, alectinib was discontinued again, resulting in the sudden decrease of serum creatinine concentration to 2.33 mg/dl (eGFR 16.9 ml/min/1.73 m²) without changing the dose of predonizolone. The serum creatinine concentration was maintained at approximately 2.3 mg/dl by use of 5 mg/day of predonizolone.

**DISCUSSION**

ALK inhibitors can cause a reversible increase of serum creatinine concentration. In fact, crizotinib rapidly produces a mean 23.9 % drop in eGFR. Upon cessation of crizotinib treatment, eGFR recovered to 84 % or more of baseline values [3, 4]. Despite this, ALK inhibitors rarely cause progressive renal insufficiency. To our knowledge, this is the first case report of alectinib-related rapid progressive glomerulonephritis.

We think that kidney impairment in this case was due to administration of alectinib. Alectinib administration has been related to progressive renal insufficiency twice in this patient. We cannot exclude some possibility of nephrotoxicity induced by pregabalin and/or codein phosphate as contributory to the first event. However, nephrotoxicities due to these agents rarely occur [6, 7]. Moreover, the second episode of kidney impairment was dramatically improved by the cessation of alectinib alone. Next, the findings from a renal biopsy enhanced the probability of alectinib-induced progressive renal insufficiency. Generally speaking, kidney disease primarily causes either glomerular or tubulointerstitial damage. However, in this case, the combination of diffuse interstitial nephritis and glomerular podocyte damage was observed. The immunofluorescent study was negative, suggesting the kidney impairment was not related to immune complex kidney disease. Of note, the serological kidney injury-related markers such as angiotensinogen converting enzyme, antidouble-stranded DNA, Sm, SS-A, SS-B, MPO-ANCA, PR3-ANCA and glomerular basement membrane antibodies were negative (data not shown). Therefore, we diagnosed this case as alectinib-induced progressive renal insufficiency.

Our case was unique because the manifestations of the first and second kidney impairment were somewhat different. Initially, proteinuria, hematuria and elevations of representative tubular injury markers in urine such as NAG and β2-MG were prominent. Cessation of alectinib was able to decrease NAG and β2-MG in the urine, but not enough to reverse kidney dysfunction. In contrast, serum creatinine concentration increased without having abnormal proteinuria, hematuria, urine NAG or β2-MG excretion during the second event. At that time, cessation of alectinib provided a dramatic improvement of kidney function. The difference may be due to glucocorticoid treatment, which could inhibit the development of urine abnormalities.

Of note, clinical and pathological manifestations were uncommon compared with other drug-induced renal insufficiency, especially at the first event. Drug-induced renal insufficiency is most commonly caused by acute interstitial nephritis [8]. Drug-induced interstitial nephritis rarely shows heavy proteinuria and hematuria. However, drugs can also damage glomerular cells directly and drug-induced glomerular disease manifests.

**Figure 1**: Representative pictures obtained from the renal biopsy and gallium-67 scintigraphy. (A) Overview of renal biopsy. Diffuse interstitial nephritis was seen. Black arrow shows crescent formation in glomeruli. Periodic acid–Schiff (PAS) stain at 40× magnification. (B) Tubular vacuolization (black arrow) and tubulitis (white arrow) were prominent. PAS stain at 200× magnification. (C) Electron microscopy revealed diffuse effacement (black arrow) at 2000× magnification. (D) Increased uptake of gallium-67 was seen in kidneys.
with proteinuria and hematuria [9]. For example, non-steroidal anti-inflammatory drugs are associated with minimal change disease (podocyte injury) in addition to ischemic acute tubular injury. However, in our case, alectinib affected podocytes and tubules, resulting in foot process effacement, crescent formation and tubulointerstitial nephritis accompanied with massive proteinuria, gross hematuria and renal insufficiency. It is rare to have such a variety of pathological changes and clinical features simultaneously in drug-induced nephropathies [8]. Conversely, the mechanism of creatinine increase at the second event is unknown due to a lack of pathological examination. However, this can be partly explained by an interference with the tubular secretion of creatinine, because another ALK inhibitor, crizotinib is thought to be a competitive inhibitor at the creatinine transporter [3, 4]. As described in 'CASE REPORT’, serum creatinine slightly increased with 2 months of crizotinib treatment, though a limited number of blood tests were performed (once a month) for this period. One year of alectinib therapy before the first event also increased serum creatinine chronically.

Alectinib demonstrated promising efficacy and was well tolerated in patients with ALK-positive disease who have disease progression or adverse effects on crizotinib [1, 10]. Crizotinib rarely causes progressive renal insufficiency, except in one case with acute tubular necrosis [11]. In this case, a small amount of proteinuria and macroscopic hematuria were detected. Pathological examination revealed acute tubular necrosis with focal mesangiolysis. Clinical manifestations and kidney pathological changes in our case were different from the crizotinib-induced progressive renal insufficiency. These findings suggest that we should recognize crizotinib and alectinib as different drugs with regard to effects and toxicity.

In conclusion, we experienced an unusual progressive renal insufficiency case related to alectinib. We must monitor kidney function when we use alectinib, even if crizotinib did not cause kidney injury in the same patient.

CONFLICT OF INTEREST STATEMENT

None declared.

FUNDING

None.

ETHICAL APPROVAL

Our institution does not require ethical approval for case reports.

CONSENT

A written consent was obtained from the patient.

GUARANTOR

K.N. is the guarantor of this article.

REFERENCES

1. Chino H, Sekine A, Kitamura H, Kato T, Ogura T. Successful treatment with alectinib after crizotinib-induced interstitial lung disease. Lung Cancer 2015;90:610–3.
2. Hida T, Nakagawa K, Seto T, Satouchi M, Nishio M, Hotta K, et al. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy. Cancer Sci 2016;107:1642–6.
3. Izzedine H, El-Fekih RK, Perazella MA. The renal effects of ALK inhibitors. Nat Rev Nephrol 2010;6:461–70.
4. Brosnan EM, Weickhardt AJ, Lu X, Maxon DA, Barón AE, Chonchol M, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 2014;120:664–74.
5. Perazella MA, Markowitz GS. Drug-induce acute interstitial nephritis. Nat Rev Nephrol 2010;6:461–70.
6. Raouf M, Atkinson TJ, Crumb MW, Fudin J. Rational dosing of gabapentin and pregabalin in chronic kidney disease. J Pain Res 2017;10:275–8.
7. Legendre M, Devilliers H, Perard L, Groh M, Nefti H, Dussol B, et al. Clinicopathologic characteristics, Figure 2: Clinical course of this case. MethylPSL, methylpredonizolone; PSL, predonizolone; eGFR, estimated glomerular filtration rate; M, month.
treatment, and outcomes of tubulointerstitial nephritis and uveitis syndrome in adults. Medicine (Baltimore) 2016; 95:e3964.

8. Pauksakon P, Fogo AB. Drug-induced nephropathies. Histopathology 2017;70:94–108.

9. Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol 2015;10:1291–9.

10. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016;17:234–42.

11. Gastaud L, Ambrosetti D, Otto J, Marquette CH, Coutts M, Hofman P, et al. Acute kidney injury following crizotinib administration for non-small-cell lung adenocarcinoma. Lung Cancer 2013;82:362–4.